EQS-News / 28/07/2021 / 16:13 UTC+8
GT20029's Successful Dosing of First Batch of Subjects in China
Suzhou, July 28, 2021 - Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing
innovative small molecule and biological therapeutics, announced today that the company has dosed the first batch of
subjects in its phase I clinical trial of GT20029 in China.
The phase I trial is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and
pharmacokinetics of GT20029 (gel/tincture) following topical single and multiple ascending dose administration in
healthy subjects.
GT20029 is the first topical Proteolysis Targeting Chimera (PROTAC) compound globally to enter the clinical stage. The
China Center for Drug Evaluation (CDE) and the U.S. Food and Drug Administration (FDA) cleared GT20029's phase I
clinical trial for treating androgenetic alopecia (AGA) and acne in April 2021 and July 2021 separately.
Dr. Youzhi Tong, Founder, Chairman and Chief Executive Officer of Kintor Pharmaceutical, commented, "The initiation of
this study represents a significant milestone for Kintor, as it is the first topical PROTAC compound to enter the
clinical stage in the world and demonstrates our progress in developing innovative therapeutics for unmet medical
needs. In preclinical studies, topical GT20029 has been shown to avoid systemic exposure and many of the side effects
of oral drugs for AGA and acne. This phase I trial will enable us evaluate the safety, recommended dosage and dosing
frequency of GT20029 to benefit those who suffer from AGA and acne."
About GT20029
GT20029 is an atopical androgen receptor (AR) degrader developed using Kintor's proprietary Proteolysis Targeting
Chimera (PROTAC) platform. The compound is inclinical studies for the treatment of AGA and acne vulgaris. IND clearance
was granted for GT20029 in the United States in July 2021.
About Kintor Pharmaceutical Limited
Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and
biological therapeutics for androgen-receptor-related disease areas with unmet medical needs, including COVID-19,
prostate, breast and liver cancer, alopecia, and acne. For more information, visit www.kintor.com.cn.
28/07/2021 Dissemination of a Marketing Press Release, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Media archive at www.todayir.com
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1222232&application_name=news(END) Dow Jones Newswires
July 28, 2021 04:13 ET (08:13 GMT)
